Effect of Maitake D-fraction in advanced laryngeal and pharyngeal cancers during concurrent chemoradiotherapy: A randomized clinical trial.
- 2022-09-01
- RCT · n = 141
- Acta biochimica Polonica 69(3)
- Qinglei Hu
- Binli Xie
- PubMed: 36070433
- DOI: 10.18388/abp.2020_5996
- High evidence
- Large Human Trial
- Clinical
The proportion of patients returning to baseline global QOL score at 6-month was increased by Maitake D-Fraction administration.
- Effect
- Beneficial
- Effect size
- Moderate
- Significant
- Yes
- Dose
- 4 capsules 3 times a day